Sign In
Buy TRUFF
$0.0200
+0 (+0%)
At Close: Jun 22, 2026
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss managementToronto, Ontario--(Newsfile Corp. - June
Toronto, Ontario--(Newsfile Corp. - June 8, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization
Filament Health will supply its standardized, patented PEX010 botanical psilocybin drug candidate, produced using proprietary extraction and stabilization methods to an independently sponsored UCSF tr
The expanded agreement adds Filament Health, a wholly owned subsidiary of Red Light Holland, as a supplying affiliate and introduces a GMP-compliant standardized microdose format of PEX010 supported b
Toronto, Ontario--(Newsfile Corp. - May 14, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario based organization advancing innovation a
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light Holland" or the "Company") is pleased to announce that shareholders overwh
Peer-reviewed results published yesterday (May 7, 2026) in JAMA Network Open demonstrate that a single dose of psilocybin meaningfully reduced
Toronto, Ontario--(Newsfile Corp. - May 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario-based organization advancing innovation an
Red Light Holland Announces Intention to Rebrand
08:30am, Monday, 04'th May 2026
New name and branding to be announced in the coming weeks, better aligned with the Company's scientific mandate and all business segments Name change resolution to be voted on by shareholders at the u
Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distribution Adds Filament's extensive intellectual property portfolio, includ
Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement
07:30am, Wednesday, 29'th Apr 2026
Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") a
Red Light Holland Announces Filament Health Shareholder Approval of Acquisition
07:30am, Monday, 27'th Apr 2026
Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to ann
Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments
08:26am, Friday, 24'th Apr 2026
Toronto, Ontario--(Newsfile Corp. - April 24, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is pleased to highlight continued expansion and execu
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
07:00am, Tuesday, 21'st Apr 2026
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.
Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of Washington Second psilocybin session showed meaningful improvements in anxiety, dep
